TY - JOUR
T1 - Chinese SLE Treatment and Research group (CSTAR) registry
T2 - Clinical significance of thrombocytopenia in Chinese patients with systemic lupus erythematosus
AU - CSTAR
AU - Jiang, N.
AU - Li, M.
AU - Zhang, M.
AU - Xu, J.
AU - Jiang, L.
AU - Gong, L.
AU - Wu, F.
AU - Gu, J.
AU - Zhao, J.
AU - Xiang, Y.
AU - Wang, Z.
AU - Zhao, Y.
AU - Zeng, X.
AU - Song, Hongmei
AU - Zeng, Xuejun
AU - Zhang, Wen
AU - Leng, Xiaomei
AU - Wu, Qingjun
AU - Su, Jinmei
AU - Shi, Qun
AU - You, Xin
AU - Zheng, Wenjie
AU - Jiang, Ying
AU - Xu, Dong
AU - Hou, You
AU - Shen, Min
AU - Chen, Hua
AU - Gan, Xiaodan
AU - Hu, Chaojun
AU - Liu, Suxian
AU - Sun, Lingyun
AU - Li, Xiangpei
AU - Li, Xiaomei
AU - Xie, Changhao
AU - Yang, Xiuyan
AU - Li, Xiaofeng
AU - Ru, Jinli
AU - Huang, Cibo
AU - Lai, Bei
AU - Wu, Donghai
AU - Zheng, Yi
AU - Wen, Xiaohong
AU - Li, Xiaoxia
AU - Duan, Ting
AU - Li, Caifeng
AU - Wu, Fengqi
AU - Huang, Feng
AU - Zhu, Jian
AU - Zhao, Dongbao
AU - Xu, Huji
N1 - Publisher Copyright:
Copyright © 2019 Jiang et al.
PY - 2019/11/1
Y1 - 2019/11/1
N2 - Objectives: To investigate the prevalence, clinical characteristics, and prognosis of thrombocytopenia (TP) in Chinese patients with systemic lupus erythematosus (SLE). Methods: The study was conducted based on the Chinese SLE Treatment and Research group (CSTAR) registry. Thrombocytopenia was defined as the platelet count<100,000/mm3 at enrollment. Severe thrombocytopenia was defined as the platelet count<50,000/mm3. The prevalence of SLE-related TP, the associations of thrombocytopenia with demographic data, organ involvements, laboratory findings, disease activity, damage, and mortality were investigated. Results: Of 2104 patients with SLE, 342 patients (16.3%) were diagnosed with thrombocytopenia. The prevalence of neuropsychiatric SLE, vasculitis, myositis, nephritis, mucocutaneous lesions, pleuritis, fever, leukocytopenia and hypocomplementemia were significantly higher in patients with thrombocytopenia (p<0.05). SLE disease activity index (SLEDAI) was significantly higher in patients with thrombocytopenia (p<0.05). Multivariate analysis showed that leukocytopenia (OR = 2.644), lupus nephritis (OR = 1.539), hypocomplementemia (OR = 1.497) and elevated SLEDAI (OR = 1.318) were independently associated with thrombocytopenia (p<0.05). Long disease duration (OR = 1.006) was an independent risk factor of severe thrombocytopenia, while anti-rRNP (OR = 0.208) was an independent protective factor of severe thrombocytopenia (p<0.05). Long disease duration was an independent risk factor of mortality in patients with thrombocytopenia (RR = 1.006). The 6-year survival of patients with thrombocytopenia was significantly lower than patients without thrombocytopenia (88.2% vs. 95.5%). Conclusions: Thrombocytopenia was a common manifestation of SLE and was associated with leukocytopenia, nephritis and severe disease activity. Severe thrombocytopenia tended to occur in long-term and relatively inactive SLE. Patients with SLE-related thrombocytopenia has a decreased long-term survival rate. Long disease duration was an independent risk factor of mortality in patients with thrombocytopenia.
AB - Objectives: To investigate the prevalence, clinical characteristics, and prognosis of thrombocytopenia (TP) in Chinese patients with systemic lupus erythematosus (SLE). Methods: The study was conducted based on the Chinese SLE Treatment and Research group (CSTAR) registry. Thrombocytopenia was defined as the platelet count<100,000/mm3 at enrollment. Severe thrombocytopenia was defined as the platelet count<50,000/mm3. The prevalence of SLE-related TP, the associations of thrombocytopenia with demographic data, organ involvements, laboratory findings, disease activity, damage, and mortality were investigated. Results: Of 2104 patients with SLE, 342 patients (16.3%) were diagnosed with thrombocytopenia. The prevalence of neuropsychiatric SLE, vasculitis, myositis, nephritis, mucocutaneous lesions, pleuritis, fever, leukocytopenia and hypocomplementemia were significantly higher in patients with thrombocytopenia (p<0.05). SLE disease activity index (SLEDAI) was significantly higher in patients with thrombocytopenia (p<0.05). Multivariate analysis showed that leukocytopenia (OR = 2.644), lupus nephritis (OR = 1.539), hypocomplementemia (OR = 1.497) and elevated SLEDAI (OR = 1.318) were independently associated with thrombocytopenia (p<0.05). Long disease duration (OR = 1.006) was an independent risk factor of severe thrombocytopenia, while anti-rRNP (OR = 0.208) was an independent protective factor of severe thrombocytopenia (p<0.05). Long disease duration was an independent risk factor of mortality in patients with thrombocytopenia (RR = 1.006). The 6-year survival of patients with thrombocytopenia was significantly lower than patients without thrombocytopenia (88.2% vs. 95.5%). Conclusions: Thrombocytopenia was a common manifestation of SLE and was associated with leukocytopenia, nephritis and severe disease activity. Severe thrombocytopenia tended to occur in long-term and relatively inactive SLE. Patients with SLE-related thrombocytopenia has a decreased long-term survival rate. Long disease duration was an independent risk factor of mortality in patients with thrombocytopenia.
UR - http://www.scopus.com/inward/record.url?scp=85075290819&partnerID=8YFLogxK
U2 - 10.1371/journal.pone.0225516
DO - 10.1371/journal.pone.0225516
M3 - Article
C2 - 31747435
AN - SCOPUS:85075290819
SN - 1932-6203
VL - 14
JO - PLoS ONE
JF - PLoS ONE
IS - 11
M1 - e0225516
ER -